The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
Major pharmacy-benefit managers generated $7.3 billion in markups on specialty drugs from pharmacies they are affiliated with ...
For the second time in less than a year, the FTC has released a highly critical report of pharmacy benefit managers, or PBMs.
Background on PBMs Recent FTC actions portray PBM practices as harmful and anticompetitive ... and playing other roles in the drug supply chain as well. As a result, they wield enormous power ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback